CervixCheck Screening Guidelines

Most people with a cervix age 21-69 who have ever had sexual contact should have a Pap test every 3 years. Transgender, non-binary, and gender diverse people may also need regular Pap tests.

	Patient Characteristics	Recommendations
AVERAGE RISK	20 years of age and under	Do not screen.
	 21 to 69 years of age and have ever had sexual contact. Sexual contact includes past or current (wanted or unwanted): intercourse oral and digital contact involving the genital and/or anal area sex with shared sex toys 	Routine screening with a Pap test every 3 years. Patients may choose to delay screening until 25 years of age as evidence suggests the harms of screening patients 21-24 may outweigh the benefits.
	70 years of age and over	Discontinue screening if the patient has had 3 negative Pap tests in the past 10 years or one negative high-risk human papillomavirus (hrHPV) test result in the last 5 years. Unscreened and underscreened patients should have 3 Pap tests, each 1 year apart. If the Pap test results are negative or there is 1 negative hrHPV test result, screening may be discontinued.
	Never had sexual contact	Do not screen. Delay screening until initiation of sexual contact.
	HPV vaccinated	Routine screening with Pap test every 3 years.
	Women who have sex with women, transgender, and non-binary people	Routine screening with Pap test every 3 years for individuals with a cervix or neo-cervix.
	Pregnant	Do not screen during pre or post-natal care unless the woman is due for a Pap test and the benefits of screening outweigh the harms of screening.
	Hysterectomy	 Do not screen if hysterectomy was: total (cervix removed), performed for a benign disease, the pathology is negative for high-grade cervical dysplasia, and there is no prior history of high-grade cervical pathology. If Pap test results or hysterectomy pathology are unavailable, screen until 2 negative vaginal vault tests are obtained.
INCREASED RISK	Immunocompromised or HIV positive	Screen with Pap test every year. All immunocompromised or HIV positive people with any abnormal result (including LSIL and ASCUS) should be referred for colposcopy.
	Previous high-grade cervical pathology (equal to or more severe than HSIL/CIN2/moderate dysplasia)	Screen with Pap test every year after discharge from colposcopy.
	Previous cervical cancer	In the absence of life-limiting comorbidities, screen every year after discharge from cancer treatment. CancerCare Manitoba's surveillance recommendations for follow-up care can be found at care.care.mb.ca/followupcare .
SYMPTOMATIC	Symptomatic, including:visual abnormalitiesabnormal bleedingabnormal discharge	Refer for colposcopy.



MANAGEMENT OF RESULTS

Pap test interpretation	Management	
Negative for intraepithelial lesion or malignancy (NILM)	Routine screening with a Pap test in 3 years.	
Atypical squamous	21 to 29 years of age	
cells of undetermined significance (ASCUS)	Repeat Pap test in 6 months Repeat Pap test in 6 months Repeat Pap test in 6 months Refer for colposcopy Refer for colposcopy	
	30 years of age and older	
hrHPV = high-risk human papillomavirus	Lab automatically tests the same specimen for hrHPV hrHPV negative hrHPV positive hrHPV invalid Refer for colposcopy hrHPV invalid Repeat Pap test in 6 months	
Low-grade squamous	21 to 49 years of age	
intraepithelial lesion (LSIL)	Repeat Pap test in 6 months Repeat Pap test in 6 months Repeat Pap test in 6 months Refer for colposcopy Refer for colposcopy	
	50 years of age and older	
	Lab automatically tests the same specimen for hrHPV hrHPV negative hrHPV negative Refer for colposcopy hrHPV invalid Repeat Pap test in 6 months	
Atypical glandular cells (AGC)	Refer for colposcopy and endocervical curettage. If patient is 35 years of age and older or has abnormal bleeding, colposcopy should also include an endometrial biopsy.	
Atypical squamous cells, cannot rule out high-grade (ASC-H)	Refer for colposcopy.	
High-grade squamous intraepithelial lesion (HSIL)	Refer for colposcopy.	
Atypical endocervical cells	Refer for colposcopy.	
Atypical endometrial cells	Refer for endometrial biopsy.	
Benign endometrial cells	If patient has abnormal bleeding: refer for endometrial biopsy. If patient does not have abnormal bleeding and is - less than 45 years of age: continue routine screening - 45 years of age and older: refer for endometrial biopsy	
Adenocarcinoma in situ (AIS)	Refer for colposcopy.	
Squamous carcinoma, adenocarcinoma, other malignant neoplasms	Refer for colposcopy.	
Unsatisfactory	Repeat Pap test in 3 months. If persistent (2 consecutive or 2 within 12 months) unsatisfactory result due to "obscuring blood" or "obscuring inflammation," refer for colposcopy.	
Absence of transformation zone cells	Screen according to cytology result.	